Tablet formulation of a phosphatidylinositol 3-kinase inhibitor
US9364475B2 · kind B2 · utility
1Cited by
0References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2015 |
| Grant date | Jun 14, 2016 |
| Priority date | — |
| Expiry date | Mar 12, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to compositions and methods that target the PI3K signaling pathway for the treatment or prevention of cancer. In one aspect, there is provided a pharmaceutical formulation comprising Polymorph E of N-(3-{[(2Z)-3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2(1H)-ylidene]sulfamoyl}phenyl)-2-methylalaninamide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.